I-Mab Biopharma announced that the first patient has been dosed in the U.S.-based Phase 1 trial of its intranasal immunotherapy agent Protollin — an investigational medication being developed to treat those with early Alzheimer’s disease. The U.S. Food and Drug Administration approved the company’s request for this safety and…
To honor their grandmother who died from Alzheimer’s in 2011, two sisters have written a children’s book to explain to kids what the disease is and how it affects those who have it. Tanya Iovino and Kiki Kouris wrote “A Kids Book About Alzheimer’s” to provide support and information…
Athira Pharma announced its Phase 2 ACT-AD trial is fully enrolled and its Phase 2/3 LIFT-AD trial has reached more than half of its target number. Both studies are evaluating the safety and efficacy of ATH-1017 in people with mild to moderate Alzheimer’s disease. Eligible adults, ages 55…
When Enma Espinosa worked during the day and her husband, Francisco Espinosa, worked the night shift, they barely saw each other. So it took longer for her to realize the small changes in his cognition were not just a normal part of aging. It wasn’t until her husband’s barber called…
A coalition of dementia organizations is calling on the U.K. government to help care-home residents maintain physical contact with loved ones during the COVID-19 pandemic. Called One Dementia Voice, the coalition acknowledges the difficulties of balancing the risk of COVID-19 against the potential harm done by isolation. However, it…
The Tau Next Generation (Tau NexGen) clinical trial will now be evaluating an anti-amyloid antibody in addition to an anti-tau antibody as a potential treatment for early onset Alzheimer’s disease, according to a press release. Lecanemab, an investigational treatment being co-developed by Eisai and Biogen, has been selected as…
The blood levels of two biomarkers of Alzheimer’s disease are significantly associated with changes in brain beta-amyloid deposits and cognitive function in early Alzheimer’s patients treated with lecanemab (BAN2401), according to a new analysis of data from a Phase 2b clinical trial. The results suggest that these blood…
An investigation vaccine for Alzheimer’s disease, ACI-35.030 by AC Immune, induced a potent production of antibodies against toxic forms of tau protein — a Alzheimer’s hallmark — in patients with early stage disease, interim results of an ongoing Phase 1b/2a trial show. “These promising results … will be invaluable as we…
At first glance, it’s a simple photo of eight small crochet works posted in three rows on a light-color backdrop and contained in a wooden frame. But there’s much more to it than that. The photo is a visual representation of the progressive effect of Alzheimer’s as put together…
A European Medicines Agency (EMA) committee has voted against approving Biogen’s Aduhelm (aducanumab) as a treatment for Alzheimer’s disease. The EMA’s Committee for Medicinal Products for Human Use, known as CHMP, is expected to issue a formal ruling based on this so-called negative trend vote after its meeting in…
Get regular updates to your inbox.